Stephen Hillerman
Overview
Explore the profile of Stephen Hillerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
You D, Hillerman S, Locke G, Chaudhry C, Stromko C, Murtaza A, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33408094
Background: Hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) has been demonstrated as a negative intracellular immune checkpoint in mediating antitumor immunity in studies with HPK1 knockout and kinase dead mice....
2.
Liu J, Curtin J, You D, Hillerman S, Li-Wang B, Eraslan R, et al.
PLoS One
. 2019 Mar;
14(3):e0212670.
PMID: 30913212
Immunotherapy has fundamentally changed the landscape of cancer treatment. Despite the encouraging results with the checkpoint modulators, response rates vary widely across tumor types, with a majority of patients exhibiting...
3.
Huang F, Chang H, Greer A, Hillerman S, Reeves K, Hurlburt W, et al.
Mol Cancer Ther
. 2014 Dec;
14(2):620-30.
PMID: 25527633
Insulin-like growth factor receptor 1 (IGF-1R)-targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical...
4.
Michaud N, Jani J, Hillerman S, Tsaparikos K, Barbacci-Tobin E, Knauth E, et al.
MAbs
. 2012 Sep;
4(6):710-23.
PMID: 23007574
The c-Met proto-oncogene is a multifunctional receptor tyrosine kinase that is stimulated by its ligand, hepatocyte growth factor (HGF), to induce cell growth, motility and morphogenesis. Dysregulation of c-Met function,...
5.
Huang F, Hurlburt W, Greer A, Reeves K, Hillerman S, Chang H, et al.
Cancer Res
. 2010 Sep;
70(18):7221-31.
PMID: 20807811
Agents targeting insulin-like growth factor-I receptor (IGF-IR), including antibodies and small-molecule inhibitors, are currently in clinical development for the treatment of cancers including sarcoma. However, development of resistance is a...
6.
Carboni J, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al.
Mol Cancer Ther
. 2009 Dec;
8(12):3341-9.
PMID: 19996272
BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L). It is currently in phase I development for the treatment...